Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Completed · Phase 1/Phase 2

Conditions studied: Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis

In brief

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

Key facts

Study ID

NCT01789320

Run by

Clearside Biomedical, Inc.

People needed

11

Starts

2013-02-01

Expected to finish

2015-03-01

Last updated by the study team

2021-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of non-infectious intermediate, posterior or pan-uveitis

You may not qualify if…

• any ocular trauma within the past 6 months in the study eye
• any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study treatment, or any prior use of Retisert™ in the study eye
• any uncontrolled systemic disease that would preclude participation in the study or put the subject at risk due to study treatment or procedures
• have a known HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated
• are monocular
• have ocular hypertension
• history of any intraocular surgery in the study eye
• presence of an anterior staphyloma in the study eye

Where it is running

• Northwestern University — Chicago, Illinois, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.